The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Polycystic ovarian syndrome (PCOS) is a complex disorder of metabolism, endocrine function, and the reproductive system that affects an estimated 1 in 10 ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. HealthDay News — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent ...

Measles may reestablish endemicity, with an estimated 851,300 cases over 25 years at current vaccination rates.

Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions.

HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment employed, according ...

Outbreak mainly affected members of communities with low measles vaccination coverage in New Mexico, Oklahoma, and Texas.

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...